Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Takeda licenses PARP inhibitor
by Lisa M. Jarvis
August 7, 2017
| A version of this story appeared in
Volume 95, Issue 32
Takeda is paying Tesaro $100 million up front for the rights in certain countries to the PARP inhibitor niraparib, which received FDA approval in April to treat recurrent ovarian cancer. Takeda gains broad rights to develop niraparib in Japan and to pursue the compound as a prostate cancer treatment in South Korea, Taiwan, Russia, and Australia. Tesaro could see another $240 million in milestone payments if niraparib is approved in those markets.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter